Pulse Biosciences Accelerates Cardiac Ablation Trials with Expanded Enrollment
Event summary
- Pulse Biosciences raised $46.8 million in Q2 2026 via ATM program, with an additional $10.7 million post-quarter.
- NANOPULSE-AF trial enrollment expanded by 19 patients to 164, maintaining early Q4 completion target.
- nPulse Cardiac Catheter System shows rapid procedure times of 7–8 minutes across multiple sites.
- CE Mark submissions for cardiac ablation systems anticipated mid-2027.
- Q2 revenue reached $434k, up sequentially from Q1.
The big picture
Pulse Biosciences is advancing its nsPFA technology through accelerated clinical trials and strategic financing, positioning itself as a disruptor in non-thermal ablation for atrial fibrillation. The company's ability to streamline workflows and reduce procedure times could set new standards in cardiac care, though success hinges on regulatory approvals and sustained investor confidence.
What we're watching
- Regulatory Timing
- Whether Pulse Biosciences can maintain its mid-2027 CE Mark approval timeline for both cardiac ablation systems.
- Clinical Momentum
- The pace at which NANOPULSE-AF trial completion will impact commercialization plans.
- Revenue Diversification
- How the Vybrance system partnership with Clayman Thyroid Center will contribute to revenue growth beyond cardiac applications.
Related topics